In AMD, complement components, amyloid-beta (Aβ), and by-products of oxidation, which are rich in drusen composition as well as lysosomal destabilization, release of cathepsins, and Alu RNA, are considered as relevant NLRP3 activators [50]. The gene discussed is NLRP3; the disease is age-related macular degeneration.